Justices Reject Merck Bid To Revive $2.5B Patent Verdict

Law360 (January 19, 2021, 9:44 AM EST) -- The U.S. Supreme Court on Tuesday refused to review a ruling that wiped out a Merck & Co. unit's $2.5 billion patent verdict, the largest in history, rebuffing the company's argument that the Federal Circuit improperly invalidates patents that cover a broad range of chemical compounds.

The justices denied a cert petition by Idenix Pharmaceuticals LLC challenging a decision invalidating its patent on a hepatitis C treatment that a jury told Gilead Sciences Inc. to pay billions for infringing.

The appeals court upheld a judge's finding that the patent did not enable a skilled person to make and use the invention,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!